目的 研究散風(fēng)活絡(luò)丸聯(lián)合依達(dá)拉奉注射液治療急性腦梗死的臨床療效。方法 選取2017年10月—2019年10月新鄉(xiāng)醫(yī)學(xué)院第一附屬醫(yī)院收治的120例急性腦梗死患者為研究對(duì)象，將所有患者隨機(jī)分為對(duì)照組和治療組，每組各60例。對(duì)照組患者靜脈滴注依達(dá)拉奉注射液，30 mg溶于生理鹽水100 mL，在30 min內(nèi)完成，1次/d；治療組患者在對(duì)照組基礎(chǔ)上口服散風(fēng)活絡(luò)丸，15丸/次，1次/d。兩組患者持續(xù)治療14 d。觀察兩組患者治療后臨床療效，對(duì)比兩組患者治療前后美國(guó)國(guó)立衛(wèi)生研究院卒中量表（NIHSS）評(píng)分、Barthel評(píng)分和炎癥因子水平。結(jié)果 治療后，治療組總有效率（96.67%）顯著高于對(duì)照組（78.33%）（P<0.05）。治療后，兩組患者NIHSS評(píng)分顯著降低，Barthel評(píng)分明顯升高（P<0.05），且治療組Barthel評(píng)分和NIHSS評(píng)分改善程度較大（P<0.05）。治療后，兩組患者C反應(yīng)蛋白（CRP）、白細(xì)胞介素-8（IL-8）和白細(xì)胞介素-10（IL-10）水平均顯著降低（P<0.05）；并且治療組血清炎性因子水平降低較多（P<0.05）。結(jié)論 散風(fēng)活絡(luò)丸聯(lián)合依達(dá)拉奉注射液治療急性腦梗死具有較好的療效，可改善臨床癥狀，降低血清炎性因子水平，安全性較高，值得在臨床上推廣應(yīng)用。

Objective To study the effect of Sanfeng Huoluo Pills combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (120 cases) with acute cerebral infarction in the First Affiliated Hospital of Xinxiang Medical University from October 2017 to October 2019 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into normal saline 100 mL, infusion completed within 30 min, once daily. Patients in the treatment group were po administered with Sanfeng Huoluo Pills on the basis of the control group, 15 pills/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and National Institute of Health stroke scale (NIHSS) score, Barthel score, and inflammatory factor in two groups were compared. Results After treatment, the total effective rate in the treatment group (96.67%) was significantly higher than that in the control group (78.33%) (P<0.05). After treatment, NIHSS scores in two groups were significantly decreased, but Barthel scores in two groups were significantly increased (P<0.05), and Barthel scores and NIHSS scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the levels of C-reactive protein (CRP), interleukin-8 (IL-8), and interleukin-10 (IL-10) in the two groups were significantly decreased (P<0.05), and the serum level of inflammatory factors in the treatment group were significantly lower than those in the control group decreased (P<0.05). Conclusion Sanfeng Huoluo Pills combined with Edaravone Injection has clinical curative effect in treatment of acute cerebral infarction, can improve the clinical symptoms, reduce the serum level of inflammatory factors, with good safety, which is worthy of clinical application.

R971

河南省科技計(jì)劃項(xiàng)目（142300410072）